Corrigendum to ‘Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after two or more HER2-directed therapies’: [ESMO Open Volume 11, Issue 7, July 2026, 107706] (S2059702926016480), (10.1016/j.esmoop.2026.107706)

초록

The authors regret that the published article contains a small number of errors. These errors do not impact the results or the conclusions of the paper. The Kaplan–Meier curve in Figure 2(E) correctly displays overall survival (OS); however, the annotation within the figure was mistakenly labeled as mPFS. The correct label is mOS (95% CI): 24.74 months (17.28–NA). The correct Fig. 2E is included here.[Figure presented] The patient numbers in Table 1 are given as 25 (80%) which is not correct for the total study population. The correct patient numbers for Table 1 are 35 (80%). The adverse event Skin reaction is given as 17 (28.6%) in Table 2. The correct percentage is 17 (38.6%). The first paragraph of the Discussion "…with a mean PFS and OS of 6.01 and 24.74 months…". This section of text should read “…with a median PFS and OS of 6.01 and 24.74 months…” as these values were estimated using the Kaplan–Meier method. Finally, in the Safety and QoL section, the questionnaire is referred to as EORTC QLQ-BR30. The correct questionnaire name is EORTC QLQ-BR23. The authors would like to apologise for any inconvenience caused. © 2026 The Author(s)